No more cosmetic injection as DCGI tightens rules - Here's what professionals can no longer do

The Drugs Controller General of India (DCGI) issued updated guidelines clarifying that injectable cosmetic products — including hyaluronic acid dermal filler...

What Happened

The Drugs Controller General of India (DCGI) issued updated guidelines clarifying that injectable cosmetic products — including hyaluronic acid dermal fillers, botulinum toxin (Botox), and collagen injections — may not be administered as cosmetics, as they fall outside the legal definition of "cosmetics" under Indian law.
Only licensed and qualified medical professionals — dermatologists, cosmetic surgeons, and plastic surgeons with relevant training — are permitted to administer such injectable products, provided the products are approved as drugs and not marketed as cosmetics.
The action follows a public notice by the Central Drugs Standard Control Organisation (CDSCO) listing injectable cosmetic products as non-compliant, and warning of legal action against manufacturers and importers marketing them as cosmetics.
The clarification was prompted by proliferation of unregulated "beauty clinics" and aesthetic centres administering injectable products without medical oversight, raising patient safety concerns.

Static Topic Bridges

Drugs and Cosmetics Act, 1940 — Definition and Regulatory Framework

The Drugs and Cosmetics Act, 1940 is the primary legislation governing the manufacture, sale, distribution, and import of drugs and cosmetics in India. It defines "cosmetic" under Section 3(aaa) as any article intended to be rubbed, poured, sprinkled, or sprayed on, or otherwise applied to, the human body for cleansing, beautifying, promoting attractiveness, or altering appearance. The critical word is "applied externally" — injectables are administered into the body, placing them outside the cosmetic definition and requiring classification as drugs.

Drugs and Cosmetics Act enacted in 1940; complemented by Drugs and Cosmetics Rules, 1945.
Section 3(aaa): cosmetic definition — external application only; does not cover products administered by injection.
Products that are injectable must be classified as drugs and regulated accordingly — requiring clinical trials, manufacturing standards (Schedule M GMP), and import registration.
Manufacture of cosmetics: regulated by State Licensing Authorities (SLAs); import of cosmetics: regulated by CDSCO (Central Licensing Authority).
The Act empowers CDSCO to take action under Sections 17, 18, and 27 for manufacture/sale of misbranded, adulterated, or spurious drugs and cosmetics.

Connection to this news: DCGI's position that injectable fillers and botulinum toxin cannot be legally classified as "cosmetics" is rooted directly in Section 3(aaa) of the Act, which restricts cosmetics to external application.

CDSCO and DCGI — Institutional Roles

The Central Drugs Standard Control Organisation (CDSCO) is the National Regulatory Authority (NRA) of India for pharmaceuticals and medical devices, functioning under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare. It is headed by the Drugs Controller General of India (DCGI). CDSCO is responsible for approval of new drugs and clinical trials (under New Drugs and Clinical Trials Rules, 2019), import registration, and standard-setting. State Licensing Authorities (SLAs) handle manufacturing licences at the state level.

CDSCO headquarters: New Delhi; functions under Section 5 of the Drugs and Cosmetics Act.
DCGI: the Central Licensing Authority under the Act; approves new drugs (Form CT-04/CT-06), vaccines, and medical devices.
New Drugs and Clinical Trials (NDCT) Rules, 2019: govern clinical trial approval, ethics committees, and compensation for trial-related injuries.
Medical Devices Rules, 2017: regulate medical devices separately; many aesthetic devices (e.g., dermal needles) fall under this framework.
CDSCO maintains a public database of approved drugs and cosmetics (SUGAM portal).

Connection to this news: CDSCO's public notice and DCGI's guidelines represent the exercise of statutory enforcement powers under the Drugs and Cosmetics Act, reaffirming the regulatory boundary between cosmetics and drugs.

Botulinum Toxin and Hyaluronic Acid — Scientific Background

Botulinum toxin (commonly marketed as Botox) is a neurotoxic protein produced by the bacterium Clostridium botulinum. In therapeutic or aesthetic use, purified and diluted formulations are injected to temporarily paralyze specific muscles by blocking acetylcholine release at neuromuscular junctions — reducing dynamic wrinkles. Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan in connective tissues; when cross-linked and formulated as a gel, it is injected as a dermal filler to restore lost volume and treat static wrinkles.

Botulinum toxin is classified as a Schedule H drug in India (prescription only) under the Drugs and Cosmetics Rules.
The US FDA classifies botulinum toxin as a drug and hyaluronic acid fillers as medical devices.
Complications from unqualified administration include: ptosis (drooping eyelid), vascular occlusion, tissue necrosis, anaphylaxis, and in rare cases death.
Schedule H drugs (Drugs and Cosmetics Rules, Appendix H): require mandatory prescription; cannot be sold over the counter.
Schedule H1 (2013 amendment): added stricter controls for certain antibiotics and drugs prone to misuse.

Connection to this news: The DCGI guidelines are scientifically grounded — these are pharmacologically active substances with serious adverse event profiles, necessitating prescription-only, medically supervised administration.

Consumer Protection and Patient Safety Framework

Beyond the Drugs and Cosmetics Act, patients harmed by improper cosmetic procedures can seek redress under the Consumer Protection Act, 2019, which includes medical services within its ambit following the Supreme Court's ruling in Indian Medical Association v. V.P. Shantha (1995) that medical professionals are subject to the Consumer Protection Act. The Medical Council of India (now replaced by the National Medical Commission, NMC, established under the NMC Act, 2020) also regulates professional standards.

Consumer Protection Act, 2019: replaced the 1986 Act; established Central Consumer Protection Authority (CCPA) with powers to recall products and penalise misleading advertisements.
IMA v. V.P. Shantha (1995): Supreme Court held that medical services fall within the definition of "service" under the Consumer Protection Act.
National Medical Commission Act, 2020: replaced the Medical Council of India (MCI); NMC regulates medical education and professional ethics.
AYUSH practitioners: not qualified to administer allopathic injectables; DCGI guidelines explicitly restrict administration to qualified allopathic specialists.

Connection to this news: The DCGI's restriction on who can administer cosmetic injectables is reinforced by the NMC's professional standards framework and the consumer protection regime — creating multi-layered accountability for practitioners.

Key Facts & Data

Cosmetic definition: Section 3(aaa), Drugs and Cosmetics Act, 1940 — external application only
Botulinum toxin classification in India: Schedule H prescription drug
Products named in CDSCO notice: hyaluronic acid fillers, botulinum toxin, collagen injections
Qualified professionals (per DCGI guidelines): dermatologists, cosmetic surgeons, plastic surgeons with relevant training
CDSCO: National Regulatory Authority under Ministry of Health and Family Welfare; headed by DCGI
Consumer Protection Act, 2019: replaced 1986 Act; includes medical services
NMC Act, 2020: replaced the Medical Council of India Act, 1956
IMA v. V.P. Shantha (1995): SC ruling extending consumer protection to medical services